Novogen's NV-128, a Novel mTOR Inhibitor, Shows Potential Activity Against Cancer Stem Cells

Published December 1, 2008, 5:10 am, Marketwire via Yahoo! Finance

Pharmaceutical company Novogen Limited today announced that work performed in collaboration with a Yale University research team led by Associate Professor Gil Mor, MD, PhD, has revealed its novel mTOR inhibitor NV-128 has the potential to act against cancer stem cells in addition to rapidly proliferating cells in established solid tumors.

Discover News | Full Story